Ministers and Senior MPs Sound the Alarm British Accords with the Trump Administration are 'Unstable'.

Ministers and senior MPs have issued warnings that the United Kingdom's recent agreements with Washington are "built on sand." This stems from revelations that a recently announced deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond broad headline terms outlined by government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, described as a "significant" achievement, exists as an "agreement in principle" without a signed legal text. It has been highlighted that the official announcements from the UK and US governments describe the deal in sharply different terms. The British version celebrates securing "zero per cent tariffs" as a singular success, while the American announcement highlights the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to increase medicine costs in return for nothing more than a verbal promise from President Trump," said David Henig, a trade expert. "It is documented he has a record of not honouring his word."

Broader Instability and a Paused Tech Deal

Concerns have been intensified by Washington's action to put on ice the major technology agreement, which was previously heralded as "a generational step-change" in the bilateral relationship. The US pointed to a lack of progress from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an earlier tariff deal have not been formally ratified by the US, despite a looming January deadline. "We have been informed that that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Behind the scenes, ministers have expressed concerns that the government's deals with Washington are lacking substance. One minister reportedly said the series of agreements as "built on sand," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, stated: "Perhaps most shocking than the administration's tactics is the UK government's naive belief that his administration is a reliable partner. The NHS is too precious to be gambled with."

A Mixed Picture of Success and Setback

Government figures have attempted to minimize the risk of the US withdrawing from the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that instability is part and parcel of dealing with the current US leadership. However, they contend that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

However, issues have emerged in carrying out the initial US-UK accord. Promised quotas on beef exports have yet to be finalized, and the commitment to "reduce steel tariffs to zero" has is still pending, with tariffs staying at 25%.

Moving forward, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.